Dennise L. Smith-Pellegrin, Department of Genetics, General Hospital of Mexico, Mexico City, Mexico María R. Rivera-Vega, Department of Genetics, General Hospital of Mexico, Mexico City, Mexico Jorge R. Cazarín-Barrientos, Department of Dermatology, General Hospital of Mexico, Mexico City, Mexico Aralí Melgarejo-Gómez, Department of Dermatology, General Hospital of Mexico, Mexico City, Mexico Olga M. Messina-Baas, Department of microsurgery anterior eye segment, Hospital General de México, Mexico City, Mexico Sergio Cuevas-Covarrubias, Department of Genetics, General Hospital of Mexico, Mexico City, Mexico


Darier disease is a clinically variable rare disease with autosomal dominant inheritance caused by mutations in ATP2A2 gene. It affects skin, mucous membranes, and nails. The onset of symptoms is during adolescence and persists through adulthood, affecting quality of life. It presents papules and small malodorous keratotic yellow to brown plaques that emerge predominantly in seborrheic areas. In the present study, we describe a patient with Darier disease successfully treated with naltrexone at low doses.



Keywords: Darier disease. Naltrexone. Darier disease treatment. ATP2A2.